



Published in final edited form as:

Tetrahedron Lett. 2017 February 15; 58(7): 642–644. doi:10.1016/j.tetlet.2017.01.006.

Synthesis and antiviral evaluation of 2',2',3',3'-tetrafluoro nucleoside analogs

Ozkan Sari^a, Leda Bassit^a, Christina Gavegnano^a, Tamara R. McBrayer^b, Louise McCormick^a, Bryan Cox^a, Steven J. Coats^b, Franck Amblard^a, and Raymond F. Schinazi^a


^aCenter for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA

^bCocrystal Pharma, Inc., 1860 Montreal Road, Tucker, GA 30084, USA

Abstract

Herein, we report the synthesis of novel 2',2',3',3'-tetrafluorinated nucleoside analogs along with their phosphoramidate prodrugs. A tetrafluoro ribose moiety was coupled with different Boc/benzoyl-protected nucleobases under Mitsunobu conditions. After deprotection, tetrafluorinated nucleosides **13b**, **14b**, **20b–22b** were reacted with phenyl-(isopropoxy-L-alaninyl)-phosphorochloridate to afford corresponding monophosphate prodrugs **24b–28b**. All synthesized compounds were evaluated against several DNA and RNA viruses including HIV, HBV, HCV, Ebola and Zika viruses.

Graphical abstract



Keywords

Nucleoside; Prodrug; Antiviral; Fluorine; Mitsunobu

Incorporation of fluorine(s) into potential drug candidates continues to be investigated by medicinal chemists and has shown the potential to confer favorable biological properties.¹ Due to the similarity in size of fluorine (147 pm) and hydrogen (120 pm), the substitution of a single hydrogen atom by a fluorine atom induces only a minor change in steric factors. However, being the most electronegative atom in the periodic table, its incorporation results in considerable electronic changes in the molecule through inductive electron withdrawing

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary Material

Supplementary data (experimental details, NMR data and HRMS) associated with this article can be found, in the online version.

effects. Furthermore, introduction of one or more atoms of fluorine (*e.g.*, CF₂) into a molecule is a viable bioisosteric replacement for a diverse set of functional groups such as carbonyl, ether and hydroxyl groups. Finally, a C–F bond is much stronger than a CH bond, which can increase the chemical and biological stability of the fluorine-containing compounds, compared to their hydrogen counterparts.

In the field of nucleoside analogs,² introduction of fluorine has proven to be successful and has led to several very widely prescribed drugs such as (–)-FTC (HIV), gemcitabine (cancer), or more recently sofosbuvir (hepatitis C virus, HCV) (Figure 1). In addition to the approved fluorinated nucleosides discussed above, several fluorine-containing analogs have been reported in the literature to have attractive antiviral profiles, although some proved too toxic for human use. Thus, 2'-β-fluoro nucleosides analogs such as FIAC, FEAU, FMAU exhibit potent activities against herpes simplex virus (HSV), hepatitis B virus (HBV), varicella zoster virus (VZV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV).³

Based on these precedents, we turned our attention toward a unique series of 2',2',3',3'-tetrafluorinated nucleoside analogs. Even though this type of highly fluorinated compounds is claimed in a patent published in 2000,⁴ their preparation is only described in a generic scheme and with no mention of any biological evaluation. Therefore, we report herein the detailed synthesis and antiviral evaluation of, not only these compounds, but also their phosphoramidate prodrugs.

2,2,3,3-Tetrafluorodideoxy ribose derivative **7** was prepared in four steps from commercially available 4-bromo-3,3,4,4-tetrafluorobut-1-ene **4** following a procedure reported by Linclau *et al.*⁵ (Scheme 1). It is noteworthy that the Sharpless dihydroxylation of the perfluorinated substrate **4** is not entirely enantioselective (reported *ee* 78%, observed 60%). Consequently, the 4'-position of the lactol **7**, obtained after cyclization of the formylated intermediate **6**, is isolated as a 8:2 mixture at the 4'-position while the α/β anomers ratio is 1:1.5. The separation of the diastereomers was not attempted at this stage. Hence, with **7** in hand, the glycosylation reaction was studied and different approaches were evaluated in order to identify the most efficient coupling conditions. Vorbrüggen type coupling of 1'-benzoyl, 1'-mesyl or 1'-triflate tetrafluorinated ribose derivative **7** with either silylated uracil or cytosine in presence of SnCl₄ (or TMSOTf) only led to the complete recovery of starting material **8**. Attempts to directly react the 1'-triflate derivative **8c** with the sodium salt of *N*²-benzoyluracil was unsuccessful as well.

In contrast, treatment of compound **7** with *N*²-benzoyluracil or *N*²-benzoylthymine under classical Mitsunobu conditions (DIAD and PPh₃ in THF) afforded the desired coupling products **9a–b** (60%) and **10a–b** (68%) respectively as a silica gel separable mixture of α/β anomers (ratio: 1.5:1) (Scheme 2). Remarkably, the desired coupling products **9** and **10** were only observed when DIAD was added slowly at –20 °C. Performing this reaction at higher temperatures led to the formation of several unidentified side products as determined by LC-MS. The isolated β anomers **9b** and **10b** were debenzoylated using methanolic ammonia to afford intermediates **11b** (91%) and **12b** (96%), which were subsequently treated with BCl₃ to give uracil and thymine analogs **13b** (94%) and **14b** (85%), respectively. Preparation of the adenine analog was initially attempted by coupling of protected lactol **7** with 6-

chloropurine using the Mitsunobu conditions described above (Scheme 3). However, even though the desired coupling product **15** was obtained in 34% yield, separation of the α/β isomers, at this stage, or after 6-amination of the purine ring (compound **16**), was found to be challenging.

Therefore, we then examined the coupling of lactol **7** with *bis*Boc adenine.⁶ Under classical Mitsunobu conditions, the reaction afforded products **17a–b** in 58% yield (Scheme 4) as a silica gel separable mixture of α/β anomers (1.5:1). Further treatment of the β -anomer **17b** with BCl_3 afforded adenine nucleoside analog **20b** in 96% yield. Likewise, the coupling with *bis*-Boc-2-amino-6-benzoyloxypurine⁷ afforded a mixture of anomers **18** (48%) that were separable by silica gel chromatography. The β -isomer **18b** was then fully deprotected in one step to give **21b** in 40% yield using BCl_3 . Finally, the preparation of cytosine analogs **19a–b** was performed in a similar manner using *bis*Boc-cytosine⁸. The separated β -anomer **19b** was subsequently deprotected to afford nucleoside analog **22b** in 82% yield.

Identification of both α and β anomers was determined by $^1\text{H-NMR}$ and 2D-NOE experiments after Mitsunobu coupling. In all cases, clear correlations were observed between 1'-protons and 4'-protons of β anomers while α anomers exhibited correlations between 1'-protons and 5'-protons. Additionally, in the case of purine analogs **17** and **18**, correlations between 8-protons and 5'-protons were also noted (Figure 2).

In order to express their therapeutic effect, nucleoside analogs usually rely on cellular kinases to be phosphorylated onto their active 5'-triphosphate forms. Among the three consecutive phosphorylations, the first phosphate addition has often been identified as the limiting step which led to the development of “protected” monophosphate nucleosides, or nucleoside prodrugs, that can by-pass this first activation step.⁹ Unlike, 5'-mono, di or triphosphate nucleosides, these prodrugs are capable of crossing the cell membrane to deliver a monophosphate nucleoside after enzymatic degradation of their biolabile group. The concept of monophosphate or phosphonate prodrugs has been clinically validated with the FDA-approval of drugs such as sofosbuvir **3** (HCV) or tenofovir disoproxyl fumarate (TDF) (HIV and HBV).

Thus, 5'-monophosphate prodrugs of nucleosides **13b**, **14b** and **20b–22b** were prepared by reaction with the chloro phosphoramidate **23** *via* two different strategies, depending on the nature of the nucleobase (Scheme 5).¹⁰ For free- NH_2 containing analogs, such as adenine, guanine and cytosine derivatives **20b**, **21b** and **22b**, *t*-BuMgCl was used to favor alkoxide formation and minimize side reactions with the amino group while the pyrimidine prodrugs **24b** and **25b** were prepared by treatment of **13b** and **14b** with *N*-methylimidazole (NMI). Full conversions were usually observed after 3 h at room temperature affording prodrugs **24b–28b**, as a R_p and S_p mixture, in yields ranging from 49% to 64%. Due to the fact that the synthesis of the tetrafluorinated sugar **7** is not completely diastereoselective at the 4'-position, ^{31}P NMR spectra for these compounds indicated the presence of four non separable diastereoisomers in a 4:1:1:4 ratio.

To determine the effects of the tetrafluoro substitution, the energetics of ring conformations were investigated using quantum mechanical calculations (Figure 3).

Consistent with previous data, the ribose and 2'-deoxyribose rings exhibited lower energies in the 3'-endo and 2'-endo conformers, respectively.¹¹ The 3'-endo and 2'-endo conformers were equal in energy for the 2',3'-dideoxyribose U and A analogs. The tetrafluoro-2',3'-dideoxyribose U and A analogs preferred the 3'-endo conformation by 0.4 – 1.2 kcal/mol. This result suggests that the tetrafluorinated ribose moiety might be a closer mimic of a ribose rather than a 2',3'-dideoxyribose.

Consequently, nucleosides **13b**, **14b**, **20b–22b** and their corresponding phosphoramidate prodrugs **24b–28b** were evaluated against a panel of DNA and RNA viruses. Hence, the screening was performed against HIV-1¹² up to 100 μ M and HBV¹² (HepAD38), HCV¹³ (clone B replicon), Ebola¹⁴ (Zaire ebolavirus replicon) and Zika¹⁵ (cytopathic effect reduction assay) viruses up to 20 μ M. In addition, cytotoxicity was determined in primary human peripheral blood mononuclear (PBM) cells, human lymphoblastoid CEM, African Green monkey Vero cells and HepG2 cells.¹⁶ Except for compound **26b** that exhibited slight toxicities in human PBM (CC₅₀ = 27 μ M) and CEM (CC₅₀ = 14 μ M) cells, none of these derivatives exhibited significant activity against these viruses nor toxicities in PBM, CEM and Vero cells up to 100 μ M.

In conclusion, five new 2',2',3',3'-tetrafluorodideoxy nucleoside analogs along with their corresponding phosphoramidate prodrugs were synthesized from tetrafluorinated lactol **7** using a key Mitsunobu reaction. We demonstrated that the use of Boc or Bz-protected bases as glycosylation partners in this reaction facilitated the separation of both α and β anomers. None of the synthesized compounds showed marked activity when tested against HIV-1, HBV, HCV, Ebola or Zika viruses.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported in part by NIH Grant 5P30-AI-50409 (CFAR). Dr. Schinazi is the Chairman and a major shareholder of Cocrystal Pharma, Inc. Emory received no funding from Cocrystal Pharma, Inc. to perform this work and vice versa.

References

1. Purser S, Moore PR, Swallow S, Gouverneur V. Chem Soc Rev. 2008; 37:320–330. [PubMed: 18197348]
2. (a) Liu P, Sharon A, Chu CK. J Fluorine Chem. 2008; 129:743–766. (b) Wójtowicz-Rajchel H. J Fluorine Chem. 2012; 143:11–48.
3. (a) Wright JA, Taylor NF, Fox JJ. J Org Chem. 1969; 34:2632–2636. [PubMed: 5803811] (b) Reichman U, Watanabe KA, Fox JJ. Carbohydr Res. 1975; 42:233–240. [PubMed: 1139559] (c) Watanabe KA, Su TL, Klein RS, Chu CK, Matsuda A, Chun MW, Lopez C, Fox JJ. J Med Chem. 1983; 26:152–156. [PubMed: 6298422] (d) Watanabe KA, Su TL, Reichman U, Greenberg N, Lopez C, Fox JJ. J Med Chem. 1984; 27:91–94. [PubMed: 6317862] (e) Perlman ME, Watanabe KA, Schinazi RF, Fox JJ. J Med Chem. 1985; 28:741–748. [PubMed: 4009596] (f) Su TL, Watanabe KA, Schinazi RF, Fox JJ. J Med Chem. 1986; 29:151–154. [PubMed: 3001306]
4. Dimagno, SG., Nebr, L. Heavily fluorinated sugar analogs. US Patent. 6,013,790. Jan 11. 2000

5. (a) Boydell AJ, Vinader V, Linclau B. *Angew Chem Int Ed.* 2004; 43:5677–5679. (b) Linclau B, Boydell AJ, Timofte RS, Brown KJ, Vinader V, Weymouth-Wilson AC. *Org Biomol Chem.* 2009; 7:803–814. [PubMed: 19194597]
6. Dey S, Garner P. *J Org Chem.* 2000; 65:7697–7699. [PubMed: 11076638]
7. Kramer RA, Bleicher KH, Wennemers H. *Helv Chim Acta.* 2012; 95:2621–2634.
8. Porcheddu A, Giacomelli G, Piredda I, Carta M, Nieddu G. *Eur J Org Chem.* 2008; 34:5786–5797.
9. Pradere U, Garnier-Amblard EC, Coats SJ, Amblard F, Schinazi RF. *Chem Rev.* 2014; 114:9154–9218. [PubMed: 25144792]
10. McGuigan C, Harris SA, Daluge SM, Gudmundsson KS, McLean EW, Burnette TC, Marr H, Hazen R, Condreay LD, Johnson L, De Clercq E, Balzarini J. *J Med Chem.* 2005; 48:3504–3515. [PubMed: 15887959]
11. Huang M, Giese TJ, Lee TS, York DM. *J Chem Theory Comput.* 2014; 10:1538–1545. [PubMed: 24803866]
12. Stuyver LJ, Lostia S, Adams M, Mathew JS, Pai BS, Grier J, Tharnish PM, Choi Y, Chong Y, Choo H, Chu CK, Otto MJ, Schinazi RF. *Antimicrob Agents Chemother.* 2002; 46:3854–3860. [PubMed: 12435688]
13. Stuyver LJ, Whitaker T, McBrayer TR, Hernandez-Santiago BI, Lostia S, Tharnish PM, Ramesh M, Chu CK, Jordan R, Shi J, Rachakonda S, Watanabe KA, Otto MJ, Schinazi RF. *Antimicrob Agents Chemother.* 2003; 47:244–254. [PubMed: 12499198]
14. Uebelhoer LS, Albariño CG, McMullan LK, Chakrabarti AK, Vincent JP, Nichol ST, Towner JS. *Antiviral Res.* 2014; 106:86–94. [PubMed: 24713118]
15. Zmurko J, Marques RE, Schols D, Verbeken E, Kaptein SJF, Neyts J. *PLoS Negl Trop Dis.* 2016; 10:1–15.
16. (a) Schinazi RF, Sommadossi JP, Saalman V, Cannon DL, Xie MW, Hart GC, Smith GA, Hahn EF. *Antimicrob Agents Chemother.* 1990; 34:1061–1067. [PubMed: 2393266] (b) Stuyver LJ, Lostia S, Adams M, Mathew J, Pai BS, Grier J, Tharnish P, Choi Y, Chong Y, Choo H, Chu CK, Otto MJ, Schinazi RF. *Antimicrob Agents Chemother.* 2002; 46:3854–3860. [PubMed: 12435688]

Highlights

- The synthesis of novel 2',2',3',3'-tetrafluoro nucleoside analogs is described
- Glycosylation reactions are achieved via Mitsunobu coupling
- Energetics of ring conformation are compared to differently substituted ribose
- Evaluation of Tetrafluoro nucleosides *in vitro* against a panel of DNA and RNA viruses




Figure 1. Structures of FDA approved fluorine containing nucleosides **1–3** and targeted 2',2',3',3'-tetrafluoro derivatives.




Figure 2.
Anomer assignment for compound **18a** and **18b** *via* NOE experiments







Figure 3. Energetics of ring conformations for differently substituted nucleoside analogs. The y-axis is the relative energy of $E[2'-endo] - E[3'-endo]$ for each analog. The dark bars represent analogs with an uracil base, and white bars are analogs with an adenine base. Nucleoside analogs that display positive values favor the *3'-endo* conformation and negative values indicate that the *2'-endo* conformer is more stable.

**Scheme 1.**


Reagents and conditions: a) $K_2OSO_4 \cdot 2H_2O$, $(DHQ)_2Pyr$, $K_3Fe(CN)_6$, $t-BuOH/H_2O$, 4 °C, 9 days, 81%; b) i) Bu_2SnO , TBAI, BnBr, toluene, reflux, 82%; ii) Formic acid, DCC, DMAP, CH_2Cl_2 , rt, 16 h, 95%; c) MeLi, THF, -78 °C, 3 h, 62%; d) BzCl, Et_3N , CH_2Cl_2 , rt, 1.5 h, 92% or MsCl, Et_3N , CH_2Cl_2 , 0 °C to rt, 16 h, 74% or Tf_2O , pyr, 0 °C to rt, 16 h, quant.

**Scheme 2.**


Reagents and conditions: a) N^{β} -BzU or N^{β} -BzT, DIAD, PPh_3 , THF, -20 °C to rt, 2 h (overall yields for both anomers); b) NH_3 , MeOH, 4 °C, 2 h; c) BCl_3 , DCM, -20 °C to rt, 3.5 h.

**Scheme 3.**

Reagents and conditions: a) 6-chloropurine, DIAD, PPh₃, THF, 2 h, rt, 34%; b) NH₃/MeOH, 80 °C, 16 h, 86%.

**Scheme 4.**

Reagents and conditions: a) Protected base (B^P), DIAD, PPh_3 , THF, $-20\text{ }^\circ\text{C}$ to rt, 2 h (overall yields for both anomers); b) BCl_3 , DCM, $-20\text{ }^\circ\text{C}$ to rt, 3.5 h.

**Scheme 5.**

Reagents and conditions: a) NMI, THF, rt, 3 h; b) *t*-BuMgCl, THF, rt, 3 h.